Abstract：
:Colon cancer remains the third most common cancer, and cause of cancer-related death in the United States. Greater public awareness and acceptance of screening programs have contributed significantly to increasingly earlier detection of colon cancer and decreased mortality. Advances made in the understanding of this disease, both in terms of its clinical behavior and molecular pathogenesis, have translated into major improvements in its therapy. Several large randomized trials during the last two decades have helped the oncology community forge a successful multi-modality treatment strategy against colon cancer. These studies have defined the role of adjuvant therapy for colon cancer after curative surgery. Despite all the advances, a large number of patients continue to succumb to this disease, and the search for better therapies is still necessary. In this article, we discuss the evolution and the current state of adjuvant chemotherapy in colon cancer and briefly review new developments.
journal_name
Curr Oncol Repjournal_title
Current oncology reportsauthors
Kumar SK,Goldberg RMdoi
10.1007/s11912-001-0007-6keywords:
subject
Has Abstractpub_date
2001-03-01 00:00:00pages
94-101issue
2eissn
1523-3790issn
1534-6269journal_volume
3pub_type
杂志文章,评审abstract：PURPOSE OF REVIEW:The aim of this review is to sum up the state of the art of urachal carcinoma (UC) in order to easily guide clinicians. RECENT FINDINGS:UC is a rare and aggressive disease with consequent few data about diagnosis and treatment. Dates are mainly based on retrospective trial and case reports with limit...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-020-0878-z
更新日期：2020-01-27 00:00:00
abstract：:Mutations in the cancer susceptibility genes BRCA1 and BRCA2 are associated with significantly increased risks of breast and ovarian cancer. Fortunately, effective strategies are available to reduce these risks, including genetic testing, which is an important consideration in determining management of patients with a...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-008-0008-9
更新日期：2008-01-01 00:00:00
abstract：:Concurrent radiation therapy and chemotherapy is the primary treatment for patients with squamous cell tumors of the anal canal, and is also employed in the neoadjuvant setting for patients with stage II and III adenocarcinoma of the rectum. There is constant clinical study involving modifications of chemoradiotherapy...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-011-0166-z
更新日期：2011-06-01 00:00:00
abstract：:Malignant pleural effusions (MPEs) are a significant source of cancer-related morbidity. Over 150,000 patients in the United States suffer from breathlessness and diminished quality of life due to MPE each year. Current management strategies are of mostly palliative value and focus on symptom control; they do not addr...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-013-0315-7
更新日期：2013-06-01 00:00:00
abstract：:The number of patients given neoadjuvant chemotherapy (NAC) followed by fertility-sparing surgery in cervical cancer is still scarce. Only a few centres perform these procedures, and thus, such procedures remain largely in the experimental stage. Patients that do not fulfil the criteria for standard fertility-sparing ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-015-0446-0
更新日期：2015-01-01 00:00:00
abstract：:The majority of patients with ovarian cancer will relapse after initial chemotherapy and will be candidates for salvage treatment. Currently, five agents show clear activity in patients with platinum- and paclitaxel-resistant disease: topotecan, oral etoposide, liposomal doxorubicin, gemcitabine, and, possibly, doceta...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-999-0012-8
更新日期：1999-09-01 00:00:00
abstract：:Osteoporosis is a disease that causes substantial morbidity and mortality for which preventive therapy is available. Women with breast cancer are at increased risk for osteoporosis for several reasons, including premature ovarian failure as a result of treatment, direct effects of chemotherapy, and effects of the brea...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-003-0086-7
更新日期：2003-01-01 00:00:00
abstract：:Variant forms of bladder cancer are non-urothelial neoplasms or urothelial carcinomas mixed with other histologies. Compared to pure urothelial carcinoma, they all present with a high stage and grade. Prognosis is variable and there is a lack of evidence regarding the ideal treatment approach, because of their relativ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-011-0161-4
更新日期：2011-06-01 00:00:00
abstract：:Although postoperative chemoradiation has a proven role in the treatment of stage II to III localized rectal cancer, recent trials have demonstrated the role of preoperative chemoradiation. A recent randomized trial has shown that preoperative chemoradiation yields higher rates of local control and sphincter preservat...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-006-0016-6
更新日期：2006-05-01 00:00:00
abstract：:Management of tumors of the salivary glands requires a detailed understanding of the anatomy and pathologic processes affecting these glands. Salivary glands give rise to benign and malignant neoplasms and are affected by a variety of systemic diseases. CT remains the most common primary imaging study; magnetic resona...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-007-0011-6
更新日期：2007-03-01 00:00:00
abstract：PURPOSE OF REVIEW:The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin's lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach. RECENT FINDINGS:In low-risk patients, RT could be omitted but, at ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-017-0592-7
更新日期：2017-05-01 00:00:00
abstract：PURPOSE OF REVIEW:The aim of this review is to highlight the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy. We focus on detailing the registration trials that have led to FDA-approved indications of anti-PD-1 and anti-PD-L1 therapies and future strategies. RECENT FINDINGS:The number of PD-1/PD-L1...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-020-00928-5
更新日期：2020-06-12 00:00:00
abstract：PURPOSE REVIEW:B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of t...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-018-0694-x
更新日期：2018-04-11 00:00:00
abstract：:Soft tissue sarcomas (STS) consist of a heterogeneous group of rare malignancies arising from mesenchymal origin. While surgical resection is the primary treatment for STS, the use of radiotherapy (RT) as an adjunctive modality has been shown to improve oncologic outcomes. Technologic improvements, such as image guida...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-016-0523-z
更新日期：2016-06-01 00:00:00
abstract：:Prostate cancer is the most common cancer and the second leading cause of cancer-related deaths in American men. Although the use of the prostate-specific antigen (PSA) test for prostate cancer screening since the 1990s has led to increased early diagnoses, the most recent studies are in conflict about the risks and b...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-010-0136-x
更新日期：2011-02-01 00:00:00
abstract：:The RAS-RAF-MEK-ERK pathway is considered to be the most important signal transduction pathway in melanoma, and alterations in this pathway via various genetic mutations, such as BRAF and NRAS mutations, are known to be important drivers of melanomagenesis. As MEK is an essential intermediary kinase protein within thi...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-013-0336-2
更新日期：2013-10-01 00:00:00
abstract：:Adjuvant treatment of patients with endometrial cancer is tailored to clinical-pathological prognostic factors. Pelvic radiation therapy for stage I endometrial cancer (EC) provides a highly significant improvement of local control, but without survival advantage. Low-risk EC patients have a very favorable prognosis, ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-011-0191-y
更新日期：2011-12-01 00:00:00
abstract：:Anaplastic oligodendrogliomas are rare primary brain tumors. However, they respond more effectively to treatment and have a better prognosis than commoner varieties. About 25 year ago, reports emerged that oligodendrogliomas can respond robustly and durably to chemotherapy with procarbazine, lomustine (CCNU), and vinc...
journal_title：Current oncology reports
pub_type： 杂志文章
doi：10.1007/s11912-012-0281-5
更新日期：2013-02-01 00:00:00
abstract：:Options for treatment of poor-prognosis or relapsed acute myeloid leukemia (AML) remain limited. Gemtuzumab ozogamicin (Mylotarg, Wyeth-Ayerst, Philadelphia, PA) is an immunoconjugate composed of recombinant humanized murine anti-CD33 antibody linked to calicheamicin, a potent cytotoxic agent. Phase II trials have sho...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-002-0030-2
更新日期：2002-09-01 00:00:00
abstract：PURPOSE OF REVIEW:Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise. RECENT FINDINGS:A limited body of preclin...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-017-0586-5
更新日期：2017-04-01 00:00:00
abstract：:The prodrug strategy has its own particular real and theoretic obstacles. Clinical strategies and research efforts have tried to approach these problems. The bystander effect, whereby nontransduced cells are affected by simple proximity to those that have received the novel gene, has enabled many prodrug systems to be...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-000-0006-z
更新日期：2000-01-01 00:00:00
abstract：:Squamous cell carcinoma of the anal canal historically has been treated with abdominoperineal resection, resulting in high rates of morbidity and local recurrence. Pioneering work led to the finding that radiation therapy (RT) combined with 5-fluorouracil (5-FU) and mitomycin results in high rates of local control and...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-009-0027-1
更新日期：2009-05-01 00:00:00
abstract：:Health-related quality of life (QOL) outcomes are frequently used by clinicians, patients, and researchers for assessing the effectiveness of an intervention. Small differences in QOL may be statistically significant but their clinical relevance remains undefined. The smallest changes in QOL scores of the anterior sku...
journal_title：Current oncology reports
pub_type： 杂志文章,meta分析,评审
doi：10.1007/s11912-012-0222-3
更新日期：2012-04-01 00:00:00
abstract：:Results of treatment for patients with non-Hodgkin's lymphomas have significantly improved over the last decade, especially following the discovery that anti-CD20 antibody therapy can significantly change the outlook for patients with both aggressive and indolent lymphomas. Although investigators have previously attem...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-010-0128-x
更新日期：2010-11-01 00:00:00
abstract：:Malnutrition is common in patients with cancer and is associated with a variety of negative outcomes. These can include reduced treatment tolerance and worsened cancer prognosis. Various aspects of aging, including sensory, physical, or psychosocial changes, place older patients at a particularly high risk for malnutr...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-017-0630-5
更新日期：2017-09-07 00:00:00
abstract：:Hypogonadism is common throughout the illness trajectory of patients with cancer. About two thirds of male patients with advanced cancer have hypothalamic-pituitary-gonadal dysfunction and low testosterone levels. Chronic inflammation, comorbidities, cachexia, chemotherapy, and medications such as opioids, megestrol a...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-014-0378-0
更新日期：2014-04-01 00:00:00
abstract：PURPOSE OF REVIEW:The aim of this article is to provide clinicians and pathologists with an understanding of the aetiopathology, pathogenesis and classification of vulval neoplasia and their molecular correlates. RECENT FINDINGS:There is an increased understanding of subcellular changes in vulvar malignancies. These p...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-019-0833-z
更新日期：2019-08-15 00:00:00
abstract：:The evolution of our ability to diagnose and classify lymphomas in an increasingly refined manner has paralleled the development of novel technologic approaches, with contemporary practice dependent upon the harnessing of a plethora of data that include microscopic, immunophenotypic, and genetic information. Although ...
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-004-0063-9
更新日期：2004-09-01 00:00:00
abstract：:Epidemiologic data presented in this review suggest the involvement of hepatitis C virus (HCV) in the patho- genesis of some histotypes of B-cell non-Hodgkin's lymphoma, in particular immunocytoma and lymphomas growing primarily in the liver and major salivary glands. Experimental data further support this hypothesis....
journal_title：Current oncology reports
pub_type： 杂志文章,评审
doi：10.1007/s11912-000-0090-0
更新日期：2000-03-01 00:00:00
abstract：:The original version of this article, which published in Current Oncology Reports, Volume 21, Issue 6, June 2019, contained an error in addressing the indication for use of neratinib in early stage breast cancer. ...
journal_title：Current oncology reports
pub_type： 已发布勘误
doi：10.1007/s11912-019-0813-3
更新日期：2019-05-17 00:00:00
